Trastuzumab: as a tool
21 studies: an imaging tracer or a test of drug response. Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung CancerRecruitingNCT07436858Phase 1Report a problem
- TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers.RecruitingNCT07009184Early Phase 1Report a problem
- HER2-PET Imaging in HER2-low Breast CancersRecruitingNCT06732336Phase 1/2Report a problem
- An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain MetastasisRecruitingNCT05376878Phase 4Report a problem
- Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy EffectivenessRecruitingNCT03321045Early Phase 1Report a problem
- Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?CompletedNCT02286843Not applicableResults postedReport a problem
- Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast CancerActive, not recruitingNCT02226276Not applicableResults postedReport a problem
- 89ZrTrastuzumab Breast Imaging With Positron Emission TomographyCompletedNCT02065609Early Phase 1Results postedReport a problem
- PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric CancerCompletedNCT02023996Not applicableResults postedReport a problem
- 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric CancerCompletedNCT01939275Not applicableResults postedReport a problem
- Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer PatientsCompletedNCT01420146Phase 1Results postedReport a problem
- Positron Emission Tomography in Women With Advanced HER2-Positive Breast CancerActive, not recruitingNCT01093612Not applicableResults postedReport a problem
- HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast CancerTerminatedNCT06595563Phase 2Report a problem
- 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot StudyCompletedNCT05955833Not applicableReport a problem
- 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111WithdrawnNCT04757090Phase 2Report a problem
- Clinical Value of 89Zr-trastuzumab PETCompletedNCT01832051Phase 2Report a problem
- HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1CompletedNCT01565200Phase 2Report a problem
- 111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast CancerTerminatedNCT01445054Early Phase 1Report a problem
- 89Zr-trastuzumab PET for Imaging the Effect of HSP90 InhibitionCompletedNCT01081600Report a problem
- Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- TrastuzumabCompletedNCT00613847Phase 1Report a problem
- PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast CancerCompletedNCT00605397Phase 1Report a problem